The first drug to treat postpartum depression (PPD) was officially approved on Monday.
They head the U.S. Food and Drug Administration, approving the first oral drug designed to “relieve” women facing physical and emotional discomfort postpartum, particularly those experiencing severe depression.
For this type of pathology, the only treatment is intravenous, but this new drug called Zurzuvae, based on the substance zuranolone, makes an important advance by offering an oral treatment option.
After multiple clinical analyses, they concluded that zuranolone significantly reduced depressive symptoms in record time.
For its part, the innovative drug will be produced by pharmaceutical companies Sage Therapeutics and Biogen, according to the BBC. Its price has yet to be determined, although it is expected to be available to patients by the end of the year.
Zurzuvae’s dosing regimen involves daily doses of 50 mg for two weeks. When clinical trials began, it was noted that symptoms began to subside within as little as three days of starting treatment. However, warnings have been issued about possible side effects, which will be detailed on the drug label.
Potential adverse effects include: drowsiness, dizziness, diarrhea, fatigue, common cold, and urinary tract infection. In addition, studies have shown that this drug may affect the ability to drive and perform other potentially dangerous activities.
Symptoms can vary in intensity and duration, and it is important to recognize them in order to seek appropriate help and support. Some of these include:
- A deep feeling of sadness.
- Extremely tired.
- Appetite changes.
- hard to fall asleep.
- Irritability and anger.
- Lack of interest or fun.
- Difficulty concentrating.
- Feelings of guilt or worthlessness.
- Social isolation.
- Negative or intrusive thoughts.